文献速递临床试验与 GCP基础与转化研究

低剂量塞来昔布治疗轻中度膝骨关节炎患者的疗效与安全性:单中心、随机、双盲、平行组对照试验方案

Efficacy and safety of low-dose celecoxib in patients with mild to moderate knee osteoarthritis: a protocol for a single-center, randomized, double-blind, parallel-group controlled trial.
PubMed 文献 · Trials · 2026-01-10

膝骨关节炎是常见的退行性关节病,伴有软骨降解和炎症。该单中心随机双盲平行组试验计划纳入200例轻中度膝骨关节炎(Kellgren-Lawrence I-III级)患者,按1:1随机接受常规剂量塞来昔布(200 mg/天)或低剂量塞来昔布(100 mg/天)治疗3个月并随访3个月,主要结局为基线至24周视觉模拟量表(VAS)疼痛强度变化。研究假设低剂量塞来昔布可保留生理性前列腺素E2水平、维持骨骼内感受以支持骨重塑平衡,同时缓解疼痛并延缓骨关节炎进展。

要点

  • 该方案拟比较塞来昔布200 mg/天与100 mg/天治疗轻中度膝骨关节炎的疗效与安全性。
  • 主要结局为基线至24周VAS疼痛强度变化,次要结局包括骨代谢标志物及影像学指标。
  • 研究假设低剂量塞来昔布可保留生理性PGE2水平并维持骨骼内感受,从而平衡镇痛与疾病修饰。

核心结论

  • 该随机对照试验方案旨在研究低剂量塞来昔布在平衡疼痛管理与疾病修饰方面的潜力,通过保留生理性PGE2水平和骨骼内感受,低剂量塞来昔布可能为常规剂量治疗提供更安全有效的替代选择,尤其适用于I-III级骨关节炎患者。

研究设计与样本

  • 单中心、随机、双盲、平行组对照试验方案,计划纳入200例诊断为轻中度膝骨关节炎(Kellgren-Lawrence I-III级)的参与者,按1:1比例随机接受常规剂量(200 mg/天)或低剂量(100 mg/天)塞来昔布连续治疗3个月,随后随访3个月。

主要发现

  • 主要结局为基线至24周视觉模拟量表(VAS)疼痛强度的变化。
  • 次要结局包括骨代谢生物标志物、西安大略和麦克马斯特大学骨关节炎指数(WOMAC)、高分辨率CT评估的软骨下骨结构、MRI评估的软骨下骨髓水肿、骨转换标志物以及血清PGE2和COX2水平。
  • 安全性通过监测不良事件的发生率和严重程度进行评估。

关键数值与推荐

  • 研究假设低剂量塞来昔布(100 mg/天)可保留生理性PGE2水平、维持支持平衡骨重塑的骨骼内感受并缓解疼痛,同时延缓骨关节炎进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Knee osteoarthritis (OA) is a prevalent degenerative joint disease characterized by cartilage degradation and inflammation, leading to pain and functional limitations. Emerging evidence suggests that physiological levels of prostaglandin E2 (PGE2) are crucial for maintaining subchondral bone remodeling balance via skeletal interoception. More and more evidence supports that standard dose or higher doses of celecoxib (≥ 200 mg/day) may disrupt this balance by significantly reducing PGE2 levels, potentially accelerating OA progression. This study aims to compare the efficacy of conventional-dose celecoxib (200 mg/day) versus low-dose celecoxib (100 mg/day) in treating patients with mild to moderate knee OA over a 3-month treatment period and 3-month follow-up. METHODS: This randomized, double-blind, parallel-group trial will enroll 200 participants diagnosed with mild to moderate knee OA (Kellgren-Lawrence grades I-III), who will be randomized in a 1:1 ratio to receive either conventional (200 mg/day) or low-dose (100 mg/day) celecoxib for consecutive 3 months. After the administration, patients were followed up for 3 months. The primary outcome will be the change in pain intensity, which was measured using the visual analog scale (VAS), from baseline to 24 weeks, evaluated via the VAS. Secondary outcomes include biomarkers of bone metabolism and safety parameters, including Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), subchondral bone structure (assessed by high-resolution CT), subchondral bone marrow edema (assessed by MRI), bone turnover markers, and serum levels of PGE2 and COX2. Safety will be assessed by monitoring the incidence and severity of adverse events. We hypothesize that low-dose celecoxib (100 mg/day) is posited to preserve physiological PGE2 levels, maintain skeletal interoception supporting balanced bone remodeling while alleviating pain, and slow the progression of OA. DISCUSSION: This RCT protocol addresses a critical gap in OA treatment by investigating the potential of low-dose celecoxib to balance pain management with disease modification. By preserving physiological PGE2 levels and skeletal interoception, low-dose celecoxib may offer a safer and more effective alternative to standard-dose treatment, particularly for patients with I-III grade OA. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2400080744. Registered on February 6, 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. He J, Yang D, Guo J, et al. Efficacy and safety of low-dose celecoxib in patients with mild to moderate knee osteoarthritis: a protocol for a single-center, randomized, double-blind, parallel-group controlled trial. Trials. 2026. PMID: 41519925. doi:10.1186/s13063-025-09394-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。